CN111939260A - 嗅觉受体or12d3作为糖尿病防治靶点的应用 - Google Patents
嗅觉受体or12d3作为糖尿病防治靶点的应用 Download PDFInfo
- Publication number
- CN111939260A CN111939260A CN201911267130.0A CN201911267130A CN111939260A CN 111939260 A CN111939260 A CN 111939260A CN 201911267130 A CN201911267130 A CN 201911267130A CN 111939260 A CN111939260 A CN 111939260A
- Authority
- CN
- China
- Prior art keywords
- diabetes
- or12d3
- insulin
- olfr109
- insulin secretion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001138802 Homo sapiens Olfactory receptor 12D3 Proteins 0.000 title claims abstract description 41
- 102100020827 Olfactory receptor 12D3 Human genes 0.000 title claims abstract description 41
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 11
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 7
- 206010010356 Congenital anomaly Diseases 0.000 claims abstract description 6
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims abstract description 6
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims abstract description 6
- 201000008980 hyperinsulinism Diseases 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 49
- 229940125396 insulin Drugs 0.000 claims description 25
- 102000004877 Insulin Human genes 0.000 claims description 24
- 108090001061 Insulin Proteins 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000003119 immunoblot Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 abstract description 22
- 108050002069 Olfactory receptors Proteins 0.000 abstract description 20
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 20
- 102000012547 Olfactory receptors Human genes 0.000 abstract description 16
- 238000011160 research Methods 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 238000011529 RT qPCR Methods 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 3
- 101150077660 OR12D3 gene Proteins 0.000 abstract description 2
- 239000003472 antidiabetic agent Substances 0.000 abstract description 2
- 230000008859 change Effects 0.000 abstract description 2
- 238000009826 distribution Methods 0.000 abstract description 2
- 201000001421 hyperglycemia Diseases 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 10
- 239000008103 glucose Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229940124280 l-arginine Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000014101 glucose homeostasis Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010656 regulation of insulin secretion Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102400000217 Asprosin Human genes 0.000 description 1
- 101800000522 Asprosin Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 102000004859 Cholecystokinin Receptors Human genes 0.000 description 1
- 108090001085 Cholecystokinin Receptors Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 1
- 101500028775 Homo sapiens Glucagon Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000033066 hyperinsulinemic hypoglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000029537 positive regulation of insulin secretion Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911267130.0A CN111939260B (zh) | 2019-12-11 | 2019-12-11 | 嗅觉受体or12d3作为糖尿病防治靶点的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911267130.0A CN111939260B (zh) | 2019-12-11 | 2019-12-11 | 嗅觉受体or12d3作为糖尿病防治靶点的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111939260A true CN111939260A (zh) | 2020-11-17 |
CN111939260B CN111939260B (zh) | 2021-12-14 |
Family
ID=73336214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911267130.0A Active CN111939260B (zh) | 2019-12-11 | 2019-12-11 | 嗅觉受体or12d3作为糖尿病防治靶点的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111939260B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016030378A1 (en) * | 2014-08-26 | 2016-03-03 | Universite De Geneve | Methods for identifying a receptor for a ligand and uses thereof |
CN105637363A (zh) * | 2013-08-01 | 2016-06-01 | 庆熙大学校产学协力团 | 预防或治疗糖尿病的药物组合物,预防或治疗糖尿病的方法,以及筛选糖尿病治疗药物的方法 |
-
2019
- 2019-12-11 CN CN201911267130.0A patent/CN111939260B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105637363A (zh) * | 2013-08-01 | 2016-06-01 | 庆熙大学校产学协力团 | 预防或治疗糖尿病的药物组合物,预防或治疗糖尿病的方法,以及筛选糖尿病治疗药物的方法 |
WO2016030378A1 (en) * | 2014-08-26 | 2016-03-03 | Universite De Geneve | Methods for identifying a receptor for a ligand and uses thereof |
Non-Patent Citations (3)
Title |
---|
KI-SUK KIM ET AL: "Activation of intestinal olfactory receptor stimulates glucagon-like peptide-1 secretion in enteroendocrine cells and attenuates hyperglycemia in type 2 diabetic mice", 《SCIENTIFIC REPORTS》 * |
NCBI: "《GeneBank》", 14 April 2001 * |
PAULE V. JOSEPH ET AL: "Comprehensive and Systematic Analysis of Gene Expression Patterns Associated with Body Mass Index", 《SCIENTIFIC REPORTS》 * |
Also Published As
Publication number | Publication date |
---|---|
CN111939260B (zh) | 2021-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats | |
KR101934328B1 (ko) | 아모디아퀸 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 | |
Kong et al. | Prevention of Streptozotocin‐Induced Diabetic Nephropathy by MG132: Possible Roles of Nrf2 and IκB | |
Xia et al. | Chrysophanol postconditioning attenuated cerebral ischemia-reperfusion injury induced NLRP3-related pyroptosis in a TRAF6-dependent manner | |
Ramasubramanian et al. | Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer’s Disease? | |
CN112316150B (zh) | 一种用于预防或治疗代谢或损伤相关疾病的药物组合物 | |
WO2024109153A1 (zh) | Ly2922470在制备预防或治疗肾脏疾病药物中的应用 | |
CN109943622B (zh) | 亚硝基谷胱甘肽还原酶的医药用途 | |
CN111939260B (zh) | 嗅觉受体or12d3作为糖尿病防治靶点的应用 | |
CN111491645B (zh) | 包含鹿角卷柏提取物、其分馏物的用于预防或治疗代谢综合症的组合物 | |
CN105031619B (zh) | 分泌因子grem2在制备2型糖尿病治疗药物中的应用 | |
CN112294835B (zh) | LncRNA-266在制备诱导棕色脂肪细胞分化药物中的应用 | |
CN111904974B (zh) | miR-574-5p在糖尿病及其相关疾病中的医药用途 | |
WO2021208551A1 (zh) | 甲状腺激素及其类似物在制备治疗镰状细胞病中的应用 | |
KR100732614B1 (ko) | 복어 추출물을 포함하는 비만 또는 당뇨성 질환의 예방또는 치료용 약학 조성물 | |
CN111705061B (zh) | 和心脏疾病相关的piRNA-P1与piRNA-P1反义核苷酸、应用和药物 | |
CN113116936A (zh) | 嗜黏蛋白艾克曼氏菌在制备β-鹅脱氧胆酸抑制剂中的应用 | |
CN105348380B (zh) | 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途 | |
CN112423772A (zh) | Rps2肽调节内皮细胞功能障碍的用途 | |
WO2021189390A1 (zh) | 一种预防/治疗2型糖尿病的药物以及用途 | |
CN112294961B (zh) | Acp5抑制剂及其在预防和治疗纤维化疾病中的用途 | |
CN111249300B (zh) | 褪黑素联合甲钴胺在治疗糖尿病创面愈合障碍中的应用 | |
CN111821420B (zh) | Cand1在制备抑制心肌细胞肥大、心力衰竭以及心肌纤维化药物中的应用 | |
CN117653709A (zh) | 一种新型肽upcp在器官纤维化治疗中的作用 | |
CN117248010A (zh) | LncRNA NEAT1在糖尿病中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230524 Address after: 215127 Room 410, Floor 4, Building M2, No. 88, Dongchang Road, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province Patentee after: Suzhou Interstellar Coupling Biotechnology Co.,Ltd. Address before: 250012 No. 44, Wenhua West Road, Shandong, Ji'nan Patentee before: SHANDONG University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240113 Address after: Building 1, 201, No. 118 Xinsha Third Road, Tangjiawan Town, High tech Zone, Zhuhai City, Guangdong Province, 519000 Patentee after: Zhuhai StarCraft Biopharmaceutical Co.,Ltd. Address before: 215127 Room 410, Floor 4, Building M2, No. 88, Dongchang Road, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province Patentee before: Suzhou Interstellar Coupling Biotechnology Co.,Ltd. |